Redeye has updated its estimates for Carasent following the Q1 2024 report, which was more or less in line with our estimates, and the revised financial targets, which were slightly more upbeat than our old forecasts, not least on how fast Carasent can scale its EBITDA-Capex margin. Carasent is starting to pick up steam, after a year of internal improvements, which now are starting to shine through in the reported numbers. We also comment on EG’s bid.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Carasent - Internal improvements are starting to show (and a bid has arrived)

© Modular Finance, source Nordic Press Releases